



SINGAPORE ASSOCIATION OF PHARMACEUTICAL INDUSTRIES

151 Chin Swee Road, #02-13A/14, Manhattan House, Singapore 169876.

T: +65-6738 0966 F: +65-6738 0977 E: admin@sapi.org.sg W: www.sapi.org.sg UEN: S66SS0025J

Singapore Association of Pharmaceutical Industries Announces Newly-Elected President and Vice President

August 25, 2021, SINGAPORE— The Singapore Association of Pharmaceutical Industries (SAPI) announced that its board of directors has elected Mr Guillermo Frydman (Managing Director, Johnson & Johnson Singapore) as President of the association, effective immediately. He previously held the position of Vice-President of the association and served as the Chair of the Public Policy Committee. He replaces outgoing President, Mr Ashish Pal, who has played a leading role in the association for the past four years. In addition, Ms Poh Hwee Tee (Managing Director, Novartis Singapore) will take over as one of the two Vice-Presidents of SAPI, joining Ms Celine Ting (Managing Director, Eisai Singapore) in that role.

As President of SAPI, Mr Frydman will represent SAPI on all matters pertaining to the association and with a focus on fostering collaborations with policy makers, healthcare providers, and patient groups to improve access to innovative medicines and vaccines. Established in 1966, SAPI currently comprises 41 members, including 33 global biopharmaceutical companies in Singapore, employing close to 10,000 people in the country. With a total projected output close to \$22 billion, the industry accounts for a fifth of Singapore's manufacturing activity and 4 percent of the country's GDP.

“Ashish has been instrumental in driving the advocacy strategies for SAPI that strengthened our industry engagement and advanced our goals as a valued and trusted industry partner in the Singapore healthcare ecosystem. I thank him for his strong leadership, commitment and significant contributions to SAPI and wish him the very best in his next role in Merck,” said SAPI's Executive Director Christina Teo. “I am confident that Guillermo will continue to lead SAPI in strengthening SAPI's strategic advocacy efforts with key stakeholders and enhancing access to innovative medicines and vaccines in Singapore as we work towards advancing Singapore's position as a global biopharmaceutical hub.”

Mr Frydman is the Managing Director of Johnson & Johnson, across all businesses (Pharma, Medical Devices, Vision Care and Consumer) in Singapore. Having worked with Johnson & Johnson for over 27 years, he brings extensive global experience which include Latin America and Southeast Asia. Ms Poh is the Managing Director for Novartis Pharma, Singapore and Asian Emerging Markets and Country President of Novartis Singapore. She also served as the Chair of SAPI's Research & Development Committee since July 2020.

“SAPI is committed to building sustainable partnerships with the government and key stakeholders across the Singapore healthcare ecosystem as we embark on the endemic road map. I am honoured to take on this role and look forward to working closely with my colleagues on the board towards enhancing dialogues with key stakeholders in pursuit of our shared vision of broadening and accelerating patients' access to innovative medicines and vaccines in Singapore,”

said Mr Frydman.

For media queries, please contact:

Ms. Christina Teo

Executive Director

Singapore Association of Pharmaceutical Industries

Tel: 6738 0966

Email: christina.teo@sapi.org.sg

Website: <https://www.sapi.org.sg/>

About SAPI

[Singapore Association of Pharmaceutical Industries \(SAPI\)](#) was founded in 1966 and was initially known as the Pharmaceutical Trade Association. In 1975, the Association changed its name to encompass a wider spectrum of pharmaceutical related business into the Association—namely the distributors, manufacturers, representative offices and affiliated companies.

Currently, SAPI comprises 41 members of which 33 are global R&D based biopharmaceutical companies in Singapore, with its members employing close to 10,000 people in the country. SAPI aims to make innovative medicine accessible to patients in Singapore. SAPI achieves this through a sustainable and valued partnership with healthcare professionals and providers, government, patient group stakeholders, and a reputation of consistent ethical behavior.